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Abstract – Macrolide resistance in Streptococcus pneumoniae and in group A streptococci (GAS) is a significant problem 
worldwide. In Serbia, data on the mechanisms of resistance and the corresponding resistance genes in streptococci are 
largely lacking. Therefore, we analyzed the distribution of macrolide resistance phenotypes and genotypes in 44 macrolide-
resistant GAS (MRGAS) and 50 macrolide-resistant S. pneumoniae (MRSP) isolates collected in the same period. The 
double disk diffusion test and PCR were used to analyze resistance phenotypes and resistance genes, respectively. Among 
MRSP, the MLSB phenotype dominated, whereas the M phenotype was the most prevalent among MRGAS isolates. Con-
sequently, in MRSP, the ermB gene was the most common (n=40, 80%), followed by the mefA gene (n=7,14%). In MRGAS 
strains, mefA dominated (n=27, 61%), followed by ermA (n=15, 33%) and ermB (n=3, 7%). In 3 MRSP isolates no resis-
tance genes were detected, while one MRGAS strain with iMLSB phenotype harbored both ermA and mefA genes.
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INTRODUCTION
Streptococcus pyogenes (Lancefield group A Strepto-
coccus, GAS) causes a broad spectrum of illnesses, 
ranging from pharyngitis to severe life-threatening 
invasive diseases (Carapetis, 2005). It is the most com-
mon cause of bacterial pharyngitis (15-30%). Strepto-
coccus pneumoniae is a significant cause of morbidity 
and mortality. Pneumococci remain the most com-
mon causative agents of community-acquired pneu-
monia (CAP), bacterial meningitis, bacteremia and 
otitis media, worldwide (Mitchell et al., 1995). 
Resistance  of  S.  pneumoniae  and  S.  pyogenes 
to  macrolides  has  become  an  increasing  problem 
worldwide. In two world surveillance studies carried 
out throughout the period from 1997 to 2000 (Gor-
don, 2002; Jacobs, 2003), the regional rates of eryth-
romycin resistance ranged from 7 to 67.3% among 
Streptococcus pneumoniae strains, and from 2.7 to 
18.6% among beta-hemolytic streptococci. 
Genes conferring macrolide resistance are usu-
ally located in mobile elements such as transposons, 
suggesting a putative transmission of macrolide-re-
sistant genes between different bacteria, particularly 
in S. pneumoniae and S. pyogenes (Gordon, 2002).
Two main well-described molecular mechanisms 
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streptococci (Leclercq, 2002): target site modifica-
tion and antibiotic efflux. Target site modification 
due to methylase activity has been linked to the pres-
ence of the erm gene. This mechanism confers cross-
resistance to macrolides, lincosamides and strepto-
gramin B (MLSB resistance). It can be constitutive 
(cMLSB),  usually  mediated  by  the  ermB  gene,  or 
inducible (iMLSB) and mediated by the ermA gene. 
The other mechanism of resistance, macrolide efflux, 
is encoded by the mefA gene and confers low-level 
resistance to 14 and 15-membered macrolides, but 
not  to  16-membered  macrolides,  lincosamides,  or 
streptogramin B (Sabharwal et al., 2006; Sutcliffe et 
al., 1996). 
Surveillance studies from European countries in-
dicate that the distribution of MLSB phenotype (due 
to erm genes) and M phenotype (due to the mefA 
gene) among clinical isolates of GAS and pneumo-
cocci greatly varies in different regions in Europe 
(Richter, 2008, Gordon, 2002; Linares, 2000; Roberts, 
1999). 
Little data are available on the mechanisms of 
macrolide resistance in GAS and S. pneumoniae in 
Serbia. Therefore, the aim of the present study was to 
examine the distribution of macrolide-resistant phe-
notypes and the related resistance genotypes among 
macrolide-resistant GAS (MRGAS) and macrolide-
resistant  S.  pneumoniae  (MRSP)  isolates  obtained 
from upper respiratory tract specimens of patients 
with pharyngitis and other upper respiratory tract 
infections. 
MATERIALS AND METHODS
Bacterial isolates
A total of 44 isolates of MRGAS and 50 isolates of 
MRSP  originating  from  patients  with  pharyngitis 
and  other  upper  respiratory  tract  infections  were 
collected from several regional laboratories between 
June 2008 and December 2009. Strains were sent to 
the National Reference Laboratory for Streptococci 
and Pneumococci for further testing. GAS identifica-
tion was confirmed on the basis of Gram stain mor-
phology, typical colony morphology, beta hemolysis, 
bacitracin  (0.04U)  sensitivity  test  (BioRad,  USA) 
and latex agglutination with group A-specific antis-
era (bioMerieux, France). Pneumococci were identi-
fied according to typical colony morphology, pres-
ence of alpha hemolysis on blood agar plates, Gram 
stain  morphology,  optochin  (BioRad,  USA)  sensi-
tivity, bile solubility test and slide agglutination test 
(bioMerieux, France). GAS and pneumococcal iso-
lates were preserved in Todd Hewitt Infusion Broth 
(Biomedics, Spain) and Brain Heart Infusion Broth 
(Biolife, Italy), respectively, containing 10% glycerol, 
and were stored at -80°C. 
Macrolide resistance phenotypes
A double disk diffusion test was used to determine 
the macrolide resistance phenotype, using erythro-
mycin (15µg) and clindamycin (2µg) disks (BioRad, 
USA) (Seppala et al., 1993; Montanari et al., 2001). 
The M phenotype was scored when the isolate was 
non-susceptible to erythromycin only. Resistance to 
both erythromycin and clindamycin was designated 
as MLSB phenotype. Inducible MLSB (iMLSB) phe-
notype was assigned if a D-shaped inhibition zone 
around the clindamycin disk was observed, while the 
absence of an inhibition zone around the two disks 
characterized  constitutive  MLSB  (cMLSB)  pheno-
type.
MICs  of  erythromycin  and  clindamycin  were 
determined using the E test (BioMerieux, France). 
Results were interpreted according to the EUCAST 
guidelines (EUCAST, 2013).
Genes of macrolide resistance
MRGAS  isolates  were  tested  for  the  presence  of 
ermA, ermB and mefA genes, using PCR, according 
to the previously published protocols (Brandt et al., 
2001; Weber et al., 2001; Perez-Trallero et al., 2007.). 
MRSP strains were screened for the ermB and mefA 
genes. After initial denaturation at 95°C for 10 min, 
35 cycles were repeated under the following condi-
tions:  denaturation  at  95°C  for  30  s,  annealing  at 
59°C for 30 s and elongation at 72°C for 30 s. Final DISTRIBUTION OF MACROLIDE-RESISTANT GENES 95
elongation was done at 72°C for 10 min. The prim-
ers used were previously described by Farrell et al. 
(2001). 
Statistical  analysis  was  performed  using  SPSS 
software, version 13.0.
RESULTS
Macrolide resistance phenotypes
On the basis of the double-disk test, MRGAS isolates 
(n=44)  were  assigned  to  the  following  resistance 
phenotypes: M phenotype – 26 isolates, (59%), iMLS 
phenotype – 15 isolates, (34%), and cMLS phenotype 
– 3 isolates, (7%). Among the 50 MRSP isolates, 8 
(16%) expressed M phenotype and 42 (84%) were as-
signed to the cMLS phenotype (Table 1).
The overall MIC range of erythromycin for both 
MRGAS  and  MRSP  isolates  was  0.5-≥256  μg/ml, 
while the range of clindamycin was 0.032-≥256 μg/
ml. The MIC ranges of erythromycin and clindamy-
cin of strains with particular phenotypes are shown 
in Table 2.
All MRGAS and MRSP strains with M phenotype 
expressed low-level macrolide resistance (MIC50 – 4 
μg/ml), while isolates with iMLSB phenotype showed 
moderate erythromycin resistance (MIC50 – 128 μg/
ml) and were susceptible to clindamycin (MIC50 – 
≤0,032 μg/ml) without induction. The cMLSB isolates 
showed a high level of both erythromycin and clin-
damycin resistance (MIC50 ≥256 μg/ml). 
The  MLSB  phenotype  was  significantly  more 
common among MRSP isolates than among MRGAS 
isolates (p < 0.05), whereas M phenotype dominated 
among  MRGAS  in  comparison  to  MRSP  isolates 
(p<0.05). 
Macrolide resistance genes
In this study, the prevalent erythromycin resistance 
gene among MRGAS isolates was mefA (n=27, 61%), 
followed by ermA (n=15, 33%) and ermB (n=3, 7%). 
The mef A gene was detected in all strains express-
ing M phenotype, while ermA and ermB genes were 
found in all strains with iMLS and cMLS phenotypes, 
respectively. One MRGAS strain with iMLSB pheno-
type harbored both ermA and mefA genes (Table 1). 
In MRSP, 7 out of 8 isolates showing M pheno-
type carried the mefA gene (14%), while among iso-
lates with cMLS phenotype, 40 out of 42 carried the 
ermB gene (80%). In three isolates (one with M phe-
notype and two with cMLS phenotype, respectively), 
no resistance genes were detected. These findings are 
summarized in Table 1.
DISCUSSION
An increase in macrolide resistance in streptococ-
cal species is becoming a serious problem in recent 
decades (Van Bambeke, 2007; Richter, 2008). In Ser-
bia, macrolide resistance in GAS is mainly due to the 
presence of the mefA gene. Our data are in agreement 
with the findings obtained in other countries, includ-
ing  Germany  (Bley,  2011),  Spain  (Tamayo,  2005), 
USA  (Green,  2006)  and  Canada  (Wierzbowski, 
2005).  However,  the  epidemiology  of  GAS  resist-
ance is not uniform in Europe. Likewise, in Norway 
(1993-2002) and in Bulgaria (1993-2002), iMLSB was 
the prevalent phenotype in GAS isolates (Littauer 
et al., 2006), and a recent study from France dem-
onstrated  predominance  of  the  cMLSB  phenotype 
(d’Humieres, 2012). Richter et al. (2008) in a study 
of macrolide resistance that included a significant 
number of GAS isolates from many European coun-
tries concluded that there is a continual increase in 
the incidence of MLSB phenotype over M phenotype 
in Europe. Therefore, the dominance of the M pheno-
type in Serbia and the low prevalence of clindamycin 
resistance among our GAS isolates are encouraging, 
since high rates of clindamycin resistance, associated 
with erm genes, may have a significant impact on the 
treatment of invasive GAS diseases.
Unlike  S.  pyogenes,  in  S.  pneumoniae  in  Ser-
bia, the MLSB phenotype due to the ermB gene was 
overrepresented  compared  to  the  M  phenotype. 
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an countries like Spain (Perez-Trallero, 2001) and 
France (Fitoussi, 2001), where the MLSB phenotype 
was dominant in pneumococci. Contrary to this, in 
the USA, the M phenotype is considerably repre-
sented among MRSP isolates, although an increase 
in MLSB phenotype in recent years has been noted 
(Jenkins, 2009). In Germany as well, efflux-mediat-
ed macrolide resistance is the predominant mecha-
nism  found  in  both  S.  pneumoniae  and  GAS,  as 
shown by several studies (Bley, 2011). On the other 
hand, the dominance of the MLSB phenotype over 
the M phenotype in pneumococci, and the opposite 
distribution of macrolide resistance phenotypes in 
GAS, as in Serbia, was also noted in several reports 
from Spain (Perez-Trallero, 2001). The explanation 
for the discrepancy of resistance mechanisms in re-
lated streptococcal species found in our study could 
be in the different clinical presentations and differ-
ences in the age of the patients: GAS isolates were 
obtained from patients with pharyngitis that were 
mostly children, while pneumococci were collected 
from patients with upper respiratory tract diseases 
(mostly adults).  
Our results confirmed a strong correlation be-
tween the M phenotype and the mefA gene and be-
tween the MLSB phenotype and erm genes in GAS, 
as well as in pneumococcal isolates. These results 
are also in accordance with the susceptibility pat-
tern of the tested isolates. A high level of resistance 
to macrolides was characteristic of the MLSB phe-
notype/erm positive isolates, while low-level resist-
ance was related to the M phenotype/mefA-positive 
strains. An association between certain macrolide 
resistance phenotypes and erythromycin resistance 
genes has already been documented (Giovanetti et 
al., 1999; Sutcliffe, 1996). Of note is that dual re-
sistance mechanisms (ermA and mefA in GAS and 
ermB and mefA genes in pneumococci) were un-
common in our study. However, in three pneumo-
coccal isolates none of resistance genes were found, 
indicating the presence of other resistance genes/
mechanisms.
Since the prevalence of the recognized pheno-
types of erythromycin-resistant S. pyogenes and S. 
pneumoniae may vary from area to area and over 
Table 1. Distribution of macrolide-resistant genes.
Isolates Phenotypes
Macrolide-resistant genes
No gene mefA ermA ermB
MRGAS
M 26 (58%) / / /
iMLS 1 (2%) 15 (33%) / /
cMLS / / 3 (7%)
MRSP
M 7 (14%) / / 1 (2%)
cMLS / / 40 (80%) 2 (4%)
Table 2. MIC values of erythromycin and clindamycin.
Phenotype Antibacterial agent MIC (µg/ml)
50% 90% Range
M erythromycin 4 16 2-16
clindamycin 0.047 0.094 0.032-0.094
iMLS erythromycin 128 128 12->256
clindamycin 0.25 0.25 0.25
cMLS erythromycin > 256 >256 >256
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time, continued monitoring is important for a better 
understanding of the epidemiology of macrolide re-
sistance in related streptococcal species. Indeed, fur-
ther studies are needed to evaluate potential changes 
of macrolide resistance phenotypes and genotypes in 
streptococci in Serbia.
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